Our Company
Our Focus
- Overview
- Neuroblastoma
- CNS/LM
- Osteosarcoma
- DIPG
- Medulloblastoma
- DSRCT
Our Research & Development
Our Patient & Family Support
- Overview
- Access to Clinical Trials
For Medical Professionals
- Overview
- Clinical Trials
For Investors

Press Releases

Investor Relations
Access denied

Year

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

NEW YORK , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting

Ymabs - Toolkit

Print Page
Email Alerts
RSS Feeds

Privacy Statement

Terms of Use

Contact Us

References

You are leaving this website

You are about to leave ymabs.com. The link will take you to a website that may be maintained by a third party, which is solely responsible for its content. Y-mAbs Therapeutics, Inc provides this link as a service to its web visitors, and is not responsible for the privacy policy or terms of use of any third-party website.

Close Continue